EKF Diagnostics is a global medical manufacturer of point-of-care (POCT) devices and tests for hemoglobin, glycated hemoglobin (HbA1c), glucose and lactate.
We have a long history in point-of-care testing and clinical chemistry reagent manufacture at our plants in Germany and the USA and are proud of our hard earned reputation for products that are easy to use, reliable and precise.
EKF Point of Care (POC) analyzers are designed for use within doctors' surgeries, clinics, hopsitals and laboratories to provide fast and accurate results at an affordable price.
EKF Central Laboratory division manufactures a wide spectrum of reagents for use in hospital laboratories across a broad portfolio of automated and semi-automated analysers.
EKF Life Sciences specializes in producing enzymes and contracted custom products for use in medical diagnostics, pharmaceuticals and industry.
All EKF's facilities are accredited by the international standards agencies that oversee the design and manufacture of medical devices. EKF-diagnostic GmbH and Stanbio Laboratory are both FDA registered facilities, whilst Stanbio is also accredited by the Canadian Medical Devices Conformity Assessment Scheme (CMDCAS).
EKF is a global company with offices in the UK, Germany, USA, Russia and China and counts with a network of more than 200 distributors covering every country.
We keep our network up-to-date with our products with constant training and attending to global events like Medica, MedLab or AACC across countries.
1990
EKF Industrie-Elektronik established. This company would go on to develop Hemo Control and Biosen.
2000
EKF Industrie-Elektronik renamed EKF-diagnostic GmbH.
2004
EKF-diagnostic sales GmbH and EKF-diagnostic Russia founded.
2006
EKF-diagnostyka Poland founded.
2010
EKF GmbH acquired by IBL plc and is listed on London Stock Exchange as EKF Diagnostics Holdings plc.
Quotient Diagnostics Ltd and Argutus Medical Ltd subsequently acquired to expand the Diabetes Care portfolio with the Quo-Lab and Quo-Test HbA1c analysers along with the predictive kidney biomarker sTNFR1.
2011
Stanbio Laboratory acquired by EKF Diagnostics Holdings plc adding a Clinical Chemistry portfolio of more than a 80 reagents, controls, calibrators, and standards, as well as a enzyme manufacturing plant in Elkhart now known as EKF Life Sciences.
2014
DiaSpect Medical AB and Separation Technology acquired to supplement EKF's hemoglobin range with DiaSpect and UltraCrit.
2016
Manufacturing consolidated into two sites - Barleben, near Magdeburg in Germany and Boerne, near San Antonio in Texas.
2018
EKF Diagnostics announces record revenues and profitability, as well as the successful floatation of spin-out, Renalytix AI, on AIM.
EKF Diagnostics Holdings plc is listed on the London Stock Exchange. For Investor Announcements, Company Information and background to the Board of Directors and Advisors visit the Investors section of this website.
Copyright © 2019 | Powered by Intergage
Please note: Not all products are available in all countries. Please check availability.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.